Off-target effects are a significant concern in gene therapy. These occur when the introduced genetic material affects genes or cellular functions other than the intended target. Advances in CRISPR technology and other gene-editing tools are helping to improve specificity and reduce the likelihood of these effects. Rigorous preclinical testing and the development of more precise delivery mechanisms are also crucial in minimizing these risks.
